Considering the recent introduction of PSMA-targeting radiopharmaceuticals labeled with β− and α+ emitters, such as [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617, and their outstanding results in metastatic castration-resistant prostate cancer patients [24,58], another interesting aspect of PSMA overexpression in ccRCC lesions is based upon the feasibility of a PSMA-targeted radioligand therapy. Here, FOLH1 is linked to prostate cancer.